A Safety Study of Oral ZSTK474 in Patients With Cancer

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary efficacy of daily oral doses of ZSTK474, an oral phosphatidylinositol 3-kinase (PI3K) inhibitor, in subjects with advanced solid malignancies.

Timeline

Start

2011-01

Primary completion

2013-12

Completion

2014-01

Drugs

Indications